帕妥珠单抗治疗HER2阳性乳腺癌的效果及安全性

Effect and Safety of Pertuzumab in the Treatment of Patients with HER2-positive Breast Cancer

目的:探究帕妥珠单抗在HER2阳性乳腺癌中的疗效、安全性及对T淋巴细胞亚群、NK细胞的影响。方法:将2021年1月—2023年1月盐城市第二人民医院收治的100例HER2阳性乳腺癌患者根据随机数字表法分为对照组和观察组,各50例。对照组采用曲妥珠单抗联合多西他赛治疗,观察组在对照组的基础上加用帕妥珠单抗。比较两组治疗总有效率、毒副反应发生率,治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原15-3(CA15-3)及糖类抗原125(CA125)]、生存质量[乳腺癌患者生命质量测定量表(FACT-B)]、T淋巴细胞亚群(CD3+及CD4+)、NK细胞。结果:观察组治疗总有效率显著高于对照组(P<0.05)。两组毒副反应发生率比较,差异均无统计学意义(P>0.05)。治疗前两组肿瘤标志物、FACT-B评分、T淋巴细胞亚群及NK细胞比较,差异均无统计学意义(P>0.05);治疗2个疗程后,观察组肿瘤标志物均显著低于对照组,FACT-B评分、T淋巴细胞亚群及NK细胞均显著高于对照组(P<0.05)。结论:帕妥珠单抗在HER2阳性乳腺癌中的疗效较好,安全性值得肯定,且对T淋巴细胞亚群及NK细胞的影响较小。

Objective:To explore the efficacy and safety of Pertuzumab in HER2-positive breast cancer and its influence on T lymphocyte subsets and NK cell.Method:A total of 100 patients with HER2-positive breast cancer admitted to Yancheng Second People's Hospital from January 2021 to January 2023 were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was treated with Trastuzumab combined with Docetaxel,and the observation group was treated with Pertuzumab on the basis of the control group.The total effective rate,the incidence of toxic and side effects,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3)and carbohydrate antigen 125(CA125)],quality of life[functional assessment of cancer therapy-breast(FACT-B)],T lymphocyte subsets(CD3+and CD4+),NK cell before and after treatment were compared bewteen the tow groups.Result:The total effective rate of observation group was significantly higher than that of control group(P<0.05).There were no significant differences in the incidence of toxic and side effects between the two groups(P>0.05).Before treatment,there were no significant differences in tumor markers,FACT-B scores,T lymphocyte subsets and NK cell between the two groups(P>0.05);after two courses of treatment,tumor markers in observation group were significantly lower than those in control group,FACT-B scores,T lymphocyte subsets and NK cell were significantly higher than those in control group(P<0.05).Conclusion:The effect of Pertuzumab in HER2-positive breast cancer is better,the safety is worthy of recognition,and its influence on T lymphocyte subsets and NK cell is less.